5 Hrs
Source:
المشهد
المشهد
Ready to play
Ready to play
The U.S. Food and Drug Administration has tentatively approved a low-cost generic version of lenacapavir for HIV prevention, administered by injection twice a year. It is expected to be available for $40 per person per year in 120 countries, compared with about $28,000 a year in the United States. Clinical trials showed the drug was more than 99.9% effective.
Notice: This Is an AI-Generated Summary
Comments (0)